Figure 3From: Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trialsForest plot for the comparison of neutropenia. FDR gemcitabine significantly increased the risk of neutropenia (RR = 1.79, 95% CI: 1.49-2.15). FDR: fixed-dose rate; CI: confidence intervals.Back to article page